LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that its partner, Taiho Pharmaceutical Co., Ltd., has filed a Japanese New Drug Application (J-NDA) with the Ministry of Health, Labour and Welfare in Japan to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer. ABRAXANE is the first and only approved protein-bound nanometer-sized solvent-free taxane and is the first commercial product to validate Abraxis’ proprietary nab™ technology platform.
